Metformin is synthetically lethal with glucose withdrawal in cancer cells

Cell Cycle

Volumn 11, Issue 15, 2012, Pages 2782-2792

  Menendez, Javier A ^a,b   Oliveras Ferraros, Cristina ^a,b   Cufí, Sílvia ^a,b   Corominas Faja, Bruna ^a,b   Joven, Jorge ^c   Martin Castillo, Begoña ^a,b   Vazquez Martin, Alejandro ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

AMPK; Breast cancer; Glucose; Metformin; Synthetic lethality

Indexed keywords

GLUCOSE; METFORMIN;

ANAEROBIC GLYCOLYSIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER STEM CELL; CANCER TISSUE; CELL CULTURE; CELL CYCLE ARREST; CONCENTRATION RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETHALITY; NONHUMAN; ONCOGENE; REVIEW; STARVATION; TUMOR MICROENVIRONMENT;

EID: 84864532063     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20948     Document Type: Review

References (105)

1. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/ cc.9.6.10994.
2. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med 2010; 10:674-91; PMID:20712585; http://dx.doi.org/10.2174/156652410792630625.
3. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48:R31-43; http://dx.doi.org/ 10.1530/JME-12-0007.
4. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29:1314-27; PMID:21301998; http://dx.doi.org/10.1007/ s12032-011-9846-7.
5. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. [Epub ahead of print]. J Clin Oncol 2012; PMID:22564993; http://dx.doi.org/10.1200/JCO.2011.39.3769.
6. Martin M, Marais R. Metformin: A Diabetes Drug for Cancer, or a Cancer Drug for Diabetics? [Epub ahead of print]. J Clin Oncol 2012; PMID:22565000; http://dx.doi.org/10.1200/JCO.2012.42.1677.
7. El Mjiyad N, Caro-Maldonado A, Ramírez-Peinado S, Muñoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene 2011; 30:253-64; PMID:20972457; http://dx.doi.org/10.1038/onc.2010.466.
8. Muñoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012; 3:e248; PMID:22237205; http://dx.doi.org/10.1038/cddis.2011.123.
9. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809.
10. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18:54-61; PMID:18387799; http://dx.doi.org/10.1016/j.gde.2008.02.003.
11. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009; 23:537-48; PMID:19270154; http://dx.doi.org/10.1101/gad.1756509.
12. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002.
13. Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr Opin Clin Nutr Metab Care 2010; 13:466-70; PMID:20473153; http://dx.doi.org/10.1097/ MCO.0b013e32833a5577.
14. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4:891-9; PMID:15516961; http://dx.doi.org/10.1038/nrc1478.
15. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008; 8:56-61; PMID:18059462; http://dx.doi.org/10.1038/nrc2255.
16. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69:4918-25; PMID:19458066; http://dx.doi.org/10.1158/0008-5472.CAN-08-4806.
17. Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci 2004; 95:547-52; PMID:15182438; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03247.x.
18. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9:665-74; PMID:19693095; http://dx.doi.org/10.1038/nrc2714.
19. Magolan J, Coster MJ. Targeting the resistance of pancreatic cancer cells to nutrient deprivation: anti-austerity compounds. Curr Drug Deliv 2010; 7:355-69; PMID:20973759; http://dx.doi.org/10.2174/156720110793566272.
20. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-98; PMID:16110319; http://dx.doi.org/10.1038/nrc1691.
21. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA doublestrand break repair. J Clin Oncol 2008; 26:3785-90; PMID:18591545; http://dx.doi.org/10.1200/JCO.2008.16.0812.
22. Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 2011; 17:854-62; PMID:21424107; http://dx.doi.org/10.2119/ molmed.2010.00240.
23. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011; 10:1192-9; PMID:21487248; http://dx.doi.org/10.4161/ cc.10.8.15273.
24. Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 2008; 7:1769-75; PMID:18594201; http://dx.doi.org/10.4161/cc.7.12.6016.
25. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA. The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 2009; 20:592-5; PMID:19153119; http://dx.doi.org/10. 1093/annonc/mdn758.
26. Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009; 11:455-9; PMID:19574203; http://dx.doi.org/10. 1007/s12094-009-0384-0.
27. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 2008; 283:3979-87; PMID:18056705; http://dx.doi.org/10.1074/jbc.M705232200.
28. Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008; 14:539-49; PMID:18977694; http://dx.doi.org/10.1016/j.molmed.2008.09.007.
29. Hardie DG. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 2011; 93:891S-6; PMID:21325438; http://dx.doi.org/10. 3945/ajcn.110.001925.
30. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13:251-62; PMID:22436748; http://dx.doi.org/10.1038/nrm3311.
31. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1:15-25; PMID:16054041; http://dx.doi.org/10.1016/j.cmet.2004.12. 003.
32. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8:774-85; PMID:17712357; http://dx.doi.org/10.1038/nrm2249.
33. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 2011; 25:1895-908; PMID:21937710; http://dx.doi.org/10.1101/gad.17420111.
34. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196:65-80; PMID:19245654; http://dx.doi.org/10.1111/j.1748-1716.2009.01972.x.
35. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling. Oncogene 2011;30:2289-303; PMID:21258412; http://dx.doi.org/10.1038/onc.2010.630.
36. Alexander A, Walker CL. The role of LKB1 and AMPK in cellular responses to stress and damage. FEBS Lett 2011; 585:952-7; PMID:21396365; http://dx.doi.org/10.1016/j.febslet.2011.03.010.
37. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003; 63:132-9; PMID:12517789.
38. Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC. Optical imaging of metabolism in HER2 over-expressing breast cancer cells. Biomed Opt Express 2012; 3:75-85; PMID:22254170; http://dx.doi.org/10.1364/BOE.3.000075.
39. Cheyne RW, Trembleau L, McLaughlin A, Smith TA. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab. Nucl Med Biol 2011; 38:339-46; PMID:21492782; http://dx.doi.org/10.1016/j.nucmedbio.2010.09.005.
40. Menendez JA, Vazquez-Martin A, Colomer R, Brunet J, Carrasco-Pancorbo A, Garcia-Villalba R, et al. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer 2007; 7:80; PMID:17490486; http://dx.doi.org/10.1186/1471- 2407-7-80.
41. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52:108-18; PMID:18171422; http://dx.doi.org/10.1111/j.1365- 2559.2007.02889.x.
42. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/ NEJMra1001389.
43. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36:206-15; PMID:20060649; http://dx.doi.org/10. 1016/j.ctrv.2009.12.002.
44. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-40; PMID:19440038; http://dx.doi.org/10. 4161/cc.8.13.8814.
45. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; 11:367-76; PMID:22189713; http://dx.doi.org/10. 4161/cc.11.2.18813.
46. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Lopez-Bonet E, et al. The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDAMB-468 triple-negative breast cancer cells. Oncol Rep 2011; 25:135-40; PMID:21109968.
47. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507-11; PMID:19752085; http://dx.doi.org/10.1158/0008-5472.CAN-09-2994.
48. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807-14; PMID:20890129; http://dx.doi.org/10. 4161/cc.9.18.13131.
49. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126:355-64; PMID:20458531; http://dx.doi.org/10.1007/s10549-010-0924-x.
50. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011; 71:3196-201; PMID:21415163; http://dx.doi.org/10.1158/0008-5472.CAN-10-3471.
51. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012; 97:E510-20; PMID:22278418; http://dx.doi.org/10.1210/jc.2011-1754.
52. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012; 5:355-64; PMID:22086681; http://dx.doi.org/10.1158/1940-6207.CAPR- 11-0299.
53. Bednar F, Simeone DM. Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res (Phila) 2012; 5:351-4; PMID:22389436; http://dx.doi.org/10.1158/1940-6207.CAPR-12-0026.
54. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2012; 2:362; PMID:22500211; http://dx.doi.org/10.1038/ srep00362.
55. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget 2012; 3:395-8; PMID:22565037.
56. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, et al. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 2012; 72:1438-48; PMID:22293754; http://dx.doi.org/10.1158/0008-5472.CAN-11-3024.
57. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells 2010; 28:721-33; PMID:20201066; http://dx.doi.org/10.1002/stem.404.
58. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, et al. Somatic oxidative bioenergetics transitions into pluripotency- dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011; 14:264-71; PMID:21803296; http://dx.doi.org/10.1016/j.cmet.2011.06.011.
59. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res 2012; 22:168-77; PMID:22064701; http://dx.doi.org/10.1038/cr.2011.177.
60. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi.org/10.4161/ cc.10.21.18128.
61. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci 2012; 1254:82-9; PMID:22548573; http://dx.doi.org/10.1111/j.1749-6632.2012.06487.x.
62. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, et al. Generation of tumorinitiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 2011; 13:R94; PMID:21952072; http://dx.doi.org/10. 1186/bcr3019.
63. Kim RJ, Nam JS. OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 2011; 27:147-52; PMID:21826175; http://dx.doi.org/10.5625/lar.2011.27.2.147.
64. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31:1354-65; PMID:21822303; http://dx.doi.org/10.1038/onc.2011.338.
65. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012; 30:833-44; PMID:22489015; http://dx.doi.org/10.1002/stem.1058.
66. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 2012; 11:974-89; PMID:22333578; http://dx.doi.org/10. 4161/cc.11.5.19450.
67. Serrano M. Metformin and reprogramming into iPSCs. Cell Cycle 2012; 11:1058-9; PMID:22395362; http://dx.doi.org/10.4161/cc.11.6.19745.
68. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, et al. Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. Cell Cycle 2012; 11:1235-46; PMID:22356767; http://dx.doi.org/10.4161/cc.11.6.19665.
69. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 2011; 13:483-91; PMID:21532889.
70. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22:659-61; PMID:17942826; http://dx.doi.org/10. 1096/fj.07-9574LSF.
71. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, et al. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010; 17:348-61; PMID:20385360; http://dx.doi.org/10.1016/j.ccr.2010.01.022.
72. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY) 2012.
73. Dilman VM, Berstein LM, Yevtushenko TP, Tsyrlina YV, Ostroumova MN, Bobrov YuF, et al. Preliminary evidence on metabolic rehabilitation of cancer patients. Arch Geschwulstforsch 1988; 58:175-83; PMID:3415435.
74. Dilman VM, Berstein LM, Ostroumova MN, Fedorov SN, Poroshina TE, Tsyrlina EV, et al. Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982; 39:13-9; PMID:7058042; http://dx.doi.org/10.1159/000225596.
75. Berstein LM. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol 2010; 6:1313-23; PMID:20799876; http://dx.doi.org/10.2217/fon.10.87.
76. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window- of-opportunity, randomized trial. Breast Cancer Res Treat 2011; 128:783-94; PMID:21655990; http://dx.doi.org/10.1007/s10549-011-1612-1.
77. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008; 105:8215-20; PMID:18378900; http://dx.doi.org/10.1073/pnas.0708100105.
78. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) 2009; 1:988-1007; PMID:20157582.
79. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 2011; 30:3305-16; PMID:21516129; http://dx.doi.org/10.1038/onc.2011.91.
80. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle 2010; 9:4474-6; PMID:21088487; http://dx.doi.org/10.4161/cc.9.22.13954.
81. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012; 4:24ra27; PMID:22323820; http://dx.doi.org/10.1126/scitranslmed.3003293.
82. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY) 2011; 3:348-62; PMID:21483040.
83. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle 2011; 10:1499-501; PMID:21566461; http://dx.doi.org/10.4161/cc.10.9.15423.
84. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, et al. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063-77; PMID:22170748.
85. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859.
86. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31:955-60; PMID:20351092; http://dx.doi.org/10.1093/carcin/bgq064.
87. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011; 71:3196-201; PMID:21415163; http://dx.doi.org/10.1158/0008-5472.CAN-10-3471.
88. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027.
89. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17:1359-70; PMID:22064426; http://dx.doi.org/10.1038/nm.2537.
90. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8:210-21; PMID:21364524; http://dx.doi.org/10.1038/nrclinonc.2011.21.
91. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010; 29:351-78; PMID:20386957; http://dx.doi.org/10.1007/s10555-010-9225-4.
92. Bjerkvig R, Johansson M, Miletic H, Niclou SP. Cancer stem cells and angiogenesis. Semin Cancer Biol 2009; 19:279-84; PMID:19818406; http://dx.doi.org/10.1016/j.semcancer.2009.09.001.
93. Brahimi-Horn MC, Bellot G, Pouysségur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011; 21:67-72; PMID:21074987; http://dx.doi.org/10.1016/j.gde.2010.10.006.
94. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDAMB-435 breast cancer model. Breast Cancer Res Treat 2009; 113:101-11; PMID:18256928; http://dx.doi.org/10.1007/s10549-008-9916-5.
95. Martin MJ, Hayward R, Viros A, Marais R. Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A. Cancer Discov 2012; 2:344-55; PMID:22576211; http://dx.doi.org/10.1158/2159-8290.CD-11-0280.
96. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011; 10:351-64; PMID:21532565; http://dx.doi.org/10.1038/nrd3374.
97. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9:218-24; PMID:17237771; http://dx.doi.org/10.1038/ncb1537.
98. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004; 96:1300-10; PMID:15339968; http://dx.doi.org/10.1093/jnci/djh243.
99. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A 2010; 107:4153-8; PMID:20160076; http://dx.doi.org/10.1073/ pnas.0913860107.
100. Jeon S-M, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485:661-5; PMID:22660331.
101. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 2010; 70:8045-54; PMID:20924112; http://dx.doi.org/10.1158/0008-5472.CAN-10-2352.
102. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70:2465-75; PMID:20215500; http://dx.doi.org/10.1158/0008-5472.CAN-09- 2782.
103. Ben Sahra I, Tanti JF, Bost F. The combination of metformin and 2 deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells. Autophagy 2010; 6:670-1; PMID:20559023; http://dx.doi.org/10. 4161/auto.6.5.12434.
104. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 2011; 10:2350-62; PMID:21992792; http://dx.doi.org/10.1158/1535- 7163.MCT-11-0497.
105. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011; 286:1-11; PMID:21059655; http://dx.doi.org/10.1074/jbc.M110.121806.